Immunogenicity and safety of a booster dose of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) compared with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in adults receiving hemodialysis who previously received hepatitis B vaccination and are not seroprotected: Results of a randomized, multicenter phase 3 study

This study compared the immunogenicity and safety of a booster dose of HepB-CpG (HEPLISAV-B® vaccine) with HepB-Eng (Engerix-B®) and HepB-AS04 (Fendrix®) in patients receiving chronic hemodialysis. This was a multicenter, randomized, open-label, phase 3 study of adults receiving hemodialysis with an...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Human Vaccines & Immunotherapeutics
المؤلفون الرئيسيون:	Matthias Girndt, Manfred Plüer, Frank Dellanna, Ann K. Michelsen, Joachim Beige, Kai Toussaint, Hubert J. Wehweck, Michael Koch, Syrus Hafezi Rachti, Justus Faust, Hans-Peter Bosselmann, Oliver Witzke, Robert S. Janssen, the HBV-18 Study Investigators
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Taylor & Francis Group 2022-11-01
الموضوعات:	cpg 1018 adjuvant hepatitis b virus vaccine hemodialysis immunogenicity safety
الوصول للمادة أونلاين:	http://dx.doi.org/10.1080/21645515.2022.2136912